Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,360.79 +13.80 (+0.26%) Dow
38,868.04 +69.05 (+0.18%) Nasdaq
17,192.53 +59.40 (+0.35%) Bitcoin USD
67,068.21 -2,323.21 (-3.35%) CMC Crypto 200
1,389.69 -51.95 (-3.61%)
TEVA Jan 2025 17.000 call
| Previous close | 2.1200 |
| Open | 1.9700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 17.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.9700 - 2.2200 |
| Contract range | N/A |
| Volume | |
| Open interest | 15.74k |
Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.
ZacksTEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
